Positron emission tomographic image measurement in schizophrenia and affective disorders

Two analytical methods for assesing regional glucography with positron emission tomography were compared in 16 patients with schizophrenia and 11 patients with affective disorders. Patients were off all medication a minimum of 14 days and an average of 39.8 days. The subjects were administered fluorine‐18‐labeled 2‐deoxyglucose just before receiving a 34‐minute one‐per‐second series of unpleasant electrical stimuli to their right forearm while resting with their eyes closed in a darkened, acoustically attenuated psychophysiological testing chamber. Following monitored stimulation in the controlled environment, the subjects were scanned and the images were converted to values of glucose use in micromoles per 100 grams per minute, according to Sokoloff's model. Data were analyzed by a four‐way analysis of variance (ANOVA) for independent groups (normal subjects, schizophrenic patients, and patients with affective disorders) and for repeated measures of slice level (supraventricular, midventricular, and infraventricular), hemisphere (right, left), and anteroposterior position (four sectors). Normal individuals and patient groups both showed a significant anteroposterior gradient in glucose use, with the highest values in the sector farthest to the front. Patients with schizophrenia and those with affective illnesses showed showed less of an anteroposterior gradient than normal individuals, especially at superior levels, which was statistically confirmed by ANOVA. Neither the group differences in whole‐brain glucose use nor the left‐right asymmetries reached statistical significance. A second technique, involving reconstruction of the lateral cortical surface, also revealed differences between schizophrenics and normal individuals in the superior frontal cortex. These results are consistent with our earlier reports of a relative hypofrontal function in schizophrenia compared with controls; they also extend the finding to the affective illnesses, the other group of major psychoses.

[1]  C. Golden,et al.  Regional cerebral blood flow in schizophrenics. Tests using the xenon Xe 133 inhalation method. , 1983, Archives of general psychiatry.

[2]  R. Mathew,et al.  Regional cerebral blood flow in schizophrenia. , 1982, Archives of general psychiatry.

[3]  M S Buchsbaum,et al.  Cerebral glucography with positron tomography. Use in normal subjects and in patients with schizophrenia. , 1982, Archives of general psychiatry.

[4]  W. Verhoeven,et al.  Short-term naloxone administration in schizophrenic and manic patients. A World Health Organization Collaborative Study. , 1982, Archives of general psychiatry.

[5]  R Coppola,et al.  A new system for gray-level surface distribution maps of electrical activity. , 1982, Electroencephalography and clinical neurophysiology.

[6]  J C Mazziotta,et al.  Quantitation in Positron Emission Computed Tomography: 5. Physical–Anatomical Effects , 1981, Journal of computer assisted tomography.

[7]  Y. Katayama,et al.  Evidence for involvement of the frontal cortex in pain-related cerebral events in cats: increase in local cerebral blood flow by noxious stimuli , 1981, Brain Research.

[8]  R. Coppola,et al.  Opiate pharmacology and individual differences. II. Somatosensory evoked potentials , 1981, PAIN.

[9]  R. Coppola,et al.  Opiate pharmacology and individual differences. I. Psychophysical pain measurements , 1981, PAIN.

[10]  E. Hoffman,et al.  Tomographic measurement of local cerebral glucose metabolic rate in humans with (F‐18)2‐fluoro‐2‐deoxy‐D‐glucose: Validation of method , 1979, Annals of neurology.

[11]  J. Morrison,et al.  Noradrenergic innervation of cerebral cortex: widespread effects of local cortical lesions. , 1979, Science.

[12]  M. Buchsbaum,et al.  Analgesia to pain stimuli in schizophrenics and its reversal by naltrexone , 1979, Psychiatry Research.

[13]  J. Endicott,et al.  A diagnostic interview: the schedule for affective disorders and schizophrenia. , 1978, Archives of general psychiatry.

[14]  M. Buchsbaum,et al.  Naloxone alters pain perception and somatosensory evoked potentials in normal subjects , 1977, Nature.

[15]  D. Ingvar,et al.  Distribution of cerebral blood flow in the dominant hemisphere during motor ideation and motor performance , 1977, Annals of neurology.

[16]  M. Reivich,et al.  THE [14C]DEOXYGLUCOSE METHOD FOR THE MEASUREMENT OF LOCAL CEREBRAL GLUCOSE UTILIZATION: THEORY, PROCEDURE, AND NORMAL VALUES IN THE CONSCIOUS AND ANESTHETIZED ALBINO RAT 1 , 1977, Journal of neurochemistry.

[17]  D. Ingvar,et al.  ABNORMALITIES OF CEREBRAL BLOOD FLOW DISTRIBUTION IN PATIENTS WITH CHRONIC SCHIZOPHRENIA , 1974, Acta psychiatrica Scandinavica.

[18]  M. Buchsbaum,et al.  Cerebral metabolic consequences of electrical cutaneous stimulation in normal individuals. , 1983, Human neurobiology.

[19]  M. Buchsbaum,et al.  Pain sensitivity and endorphins in functional psychoses. , 1981, Modern problems of pharmacopsychiatry.

[20]  M. Buchsbaum,et al.  Alterations of evoked potentials link research in attention dysfunction to peptide response symptoms of schizophrenia. , 1980, Advances in biochemical psychopharmacology.

[21]  A. Hirano,et al.  AN ATLAS OF THE HUMAN BRAIN FOR COMPUTERIZED TOMOGRAPHY. , 1978 .

[22]  D. Ingvar,et al.  ACTIVATION PATTERNS INDUCED IN THE DOMINANT HEMISPHERE BY SKIN STIMULATION , 1976 .

[23]  C. Spielberger,et al.  Manual for the State-Trait Anxiety Inventory , 1970 .